Literature DB >> 30066882

Upregulation and activation of p53 by erastin‑induced reactive oxygen species contribute to cytotoxic and cytostatic effects in A549 lung cancer cells.

Chaoli Huang1, Mengchang Yang2, Jia Deng2, Peng Li2, Wenjie Su2, Rong Jiang2.   

Abstract

The tumour‑suppressor protein p53 is a key regulator of multiple cellular processes and exerts its tumour‑suppressor function by inducing apoptotic cell death. However, emerging evidence indicates that p53 is also involved in inducing ferroptosis, which is a unique iron‑dependent form of non‑apoptotic cell death triggered by the RAS‑selective lethal small molecule erastin. Previous studies have shown that erastin exposure induces increased ROS accumulation and oxidative stress. In the present study, we incubated A549 cells with erastin and detected ROS accumulation. Semi‑quantitative western blotting was performed to analyse the effect of the induced ROS on p53 activity. To determine how ROS activate p53, NAC, an ROS scavenger, and KU‑55933, an ATM kinase inhibitor, were employed to co‑incubate with erastin, followed by western blot analysis. Either p53 or SLC7A11 siRNA was introduced into A549 cells to silence the target‑gene expression, followed by ROS detection to illustrate the regulatory role of ROS‑activated p53 on its target gene SLC7A11. Annexin V‑FITC/PI staining was performed to detect the induction of apoptotic cell death by erastin exposure. To further assess the effects of erastin treatment on cellular proliferation, EdU staining and cell cycle flow cytometric analysis were performed. Erastin exposure upregulated and activated p53 and thus, transcriptionally activated its downstream target genes, including p21 and Bax, in lung cancer A549 cells dependent on erastin‑induced ROS. Subsequently, activated p53 by erastin treatment suppressed SLC7A11 and induced ROS accumulation, indicating the potential feedback loop between p53 and erastin‑induced ROS. By employing the caspase inhibitor Z‑VAD‑FMK, it was revealed that erastin‑induced p53 contributed to both ferroptotic and apoptotic cell death and inhibited cell proliferation via arresting the cell cycle at G1 phase. Collectively, these results indicated that p53 may contribute to the cytotoxic and cytostatic effects associated with establishing a feedback loop with ROS induced by erastin.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30066882     DOI: 10.3892/or.2018.6585

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  32 in total

Review 1.  Autophagy-Dependent Ferroptosis: Machinery and Regulation.

Authors:  Jiao Liu; Feimei Kuang; Guido Kroemer; Daniel J Klionsky; Rui Kang; Daolin Tang
Journal:  Cell Chem Biol       Date:  2020-03-10       Impact factor: 8.116

2.  Genomic Analysis Reveals the Prognostic and Immunotherapeutic Response Characteristics of Ferroptosis in Lung Squamous Cell Carcinoma.

Authors:  Yinhe Feng; Xingyu Xiong; Yubin Wang; Ding Han; Chunfang Zeng; Hui Mao
Journal:  Lung       Date:  2022-05-05       Impact factor: 2.584

Review 3.  Multifaceted Roles of Ferroptosis in Lung Diseases.

Authors:  Yi Li; Ying Yang; Yongfeng Yang
Journal:  Front Mol Biosci       Date:  2022-06-24

Review 4.  p53 in ferroptosis regulation: the new weapon for the old guardian.

Authors:  Yanqing Liu; Wei Gu
Journal:  Cell Death Differ       Date:  2022-01-27       Impact factor: 12.067

Review 5.  System Xc-: a key regulatory target of ferroptosis in cancer.

Authors:  Man-Ru Liu; Wen-Tao Zhu; Dong-Sheng Pei
Journal:  Invest New Drugs       Date:  2021-01-27       Impact factor: 3.850

Review 6.  Molecular Mechanisms of Ferroptosis and Its Role in Pulmonary Disease.

Authors:  Ningning Tao; Kang Li; Jingjing Liu
Journal:  Oxid Med Cell Longev       Date:  2020-06-26       Impact factor: 6.543

Review 7.  The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy.

Authors:  Tiejun Wang; Yan Jiao; Yuechen Zhao; Yanqing Li; Ruifeng Zhang; Feng Wang
Journal:  Onco Targets Ther       Date:  2020-06-11       Impact factor: 4.147

Review 8.  The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression.

Authors:  Yuqing Wu; Siwei Zhang; Xiaoxiao Gong; Samantha Tam; Desheng Xiao; Shuang Liu; Yongguang Tao
Journal:  Mol Cancer       Date:  2020-02-27       Impact factor: 27.401

Review 9.  A Promising Future of Ferroptosis in Tumor Therapy.

Authors:  Hui Wang; Danfeng Lin; Qianqian Yu; Zhouqi Li; Cameron Lenahan; Ying Dong; Qichun Wei; Anwen Shao
Journal:  Front Cell Dev Biol       Date:  2021-06-09

Review 10.  Emerging mechanisms and targeted therapy of ferroptosis in cancer.

Authors:  Haiyan Wang; Yan Cheng; Chao Mao; Shuang Liu; Desheng Xiao; Jun Huang; Yongguang Tao
Journal:  Mol Ther       Date:  2021-03-29       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.